Diagnostic test maker Tosoh Bioscience Inc. has received a warning letter from the Food & Drug Administration over record-keeping violations and failing to follow industry manufacturing standards at its Grove City, Ohio, plant.
Among Tosoh’s violations cited by the FDA was the “misbranding” of a diabetes test. The FDA said Tosoh didn’t notify the agency of its intention to introduce the device to commercial distribution.